Latest news
The Bull Case For AbbVie (ABBV) Could Change Following EU Approval Of Rinvoq For Vitiligo - webull.comwebull.com · Tue, 04 Aug 2026 08:36:41 GMTAbbVie’s RINVOQ wins EU approval as first systemic treatment for vitiligo - Indian Pharma PostIndian Pharma Post · Sat, 01 Aug 2026 07:00:00 GMTAbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:00:00 GMTAbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo - PMLiVEPMLiVE · Fri, 31 Jul 2026 07:00:00 GMTPfizer's ritlecitinib advances to become first oral systemic therapy for nonsegmental vitiligo - AllSciAllSci · Thu, 30 Jul 2026 16:35:55 GMTPfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie - Fierce PharmaFierce Pharma · Thu, 30 Jul 2026 07:00:00 GMTEU Approves Upadacitinib as First Systemic Treatment for Vitiligo - The Dermatology DigestThe Dermatology Digest · Wed, 29 Jul 2026 15:04:34 GMTRINVOQ Becomes EU's First and Only Systemic Medication for Vitiligo - stocktitan.netstocktitan.net · Wed, 29 Jul 2026 07:00:00 GMT